These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. The sickle erythrocyte in double jeopardy: autoxidation and iron decompartmentalization. Hebbel RP Semin Hematol; 1990 Jan; 27(1):51-69. PubMed ID: 2405496 [No Abstract] [Full Text] [Related]
25. Clinical Pharmacology for Pediatricians. II. Antisickling agents, with special reference to new vasoerythroactive drugs. Cho YW; Aviado DM J Clin Pharmacol; 1982 Jan; 22(1):1-13. PubMed ID: 7037870 [No Abstract] [Full Text] [Related]
26. [Sickle cell anemia and the affinity of the blood for oxygen]. Pocidalo JJ; Sinet M C R Seances Soc Biol Fil; 1979; 173(2):303-13. PubMed ID: 159755 [TBL] [Abstract][Full Text] [Related]
27. Effect of BW12C on oxygen affinity of haemoglobin in sickle-cell disease. Keidan AJ; Franklin IM; White RD; Joy M; Huehns ER; Stuart J Lancet; 1986 Apr; 1(8485):831-4. PubMed ID: 2870317 [TBL] [Abstract][Full Text] [Related]
28. Prevention and treatment of sickle cell crisis by induced hyponatremia. Rosa RM; Bierer B; Thomas R; Stoff JS; Kruskall M; Robinson S; Bunn HF; Epstein FH Trans Assoc Am Physicians; 1980; 93():164-74. PubMed ID: 7245573 [No Abstract] [Full Text] [Related]
29. Sickle cell leg ulcers: current pathophysiologic concepts. Gabuzda TG Int J Dermatol; 1975 Jun; 14(5):322-5. PubMed ID: 238913 [No Abstract] [Full Text] [Related]
31. Spectrum of fetal hemoglobin responses in sickle cell patients treated with hydroxyurea: the National Institutes of Health experience. Rodgers GP Semin Oncol; 1992 Jun; 19(3 Suppl 9):67-73. PubMed ID: 1379375 [TBL] [Abstract][Full Text] [Related]
32. Effect of cyanate on sickling. May A; Bellingham AJ; Huehns ER; Beaven GH Lancet; 1972 Mar; 1(7752):658-61. PubMed ID: 4125163 [No Abstract] [Full Text] [Related]
33. Treatment of sickle cell anemia with hydroxyurea and erythropoietin. Goldberg MA; Brugnara C; Dover GJ; Schapira L; Charache S; Bunn HF N Engl J Med; 1990 Aug; 323(6):366-72. PubMed ID: 1695325 [TBL] [Abstract][Full Text] [Related]
34. Comparisons of the kinetic stability of normal and sickle cell human hemoglobins at extremes of pH. Jones DD; McGrath WP; Carroll D; Steinhardt J Biochemistry; 1973 Sep; 12(20):3818-24. PubMed ID: 4745648 [No Abstract] [Full Text] [Related]
35. Clinical Implications of the Association of Fetal Hemoglobin with Peripheral Oxygen Saturation in Sickle Cell Disease. Abdulmalik O; Ataga KI EBioMedicine; 2017 Oct; 24():26-27. PubMed ID: 28890145 [No Abstract] [Full Text] [Related]
37. The clinical pathophysiology of sickle cell disease. Embury SH Annu Rev Med; 1986; 37():361-76. PubMed ID: 2423018 [TBL] [Abstract][Full Text] [Related]
38. Time resolved absorption study of the reaction of hydroxyurea with sickle cell hemoglobin. Kim-Shapiro DB; King SB; Bonifant CL; Kolibash CP; Ballas SK Biochim Biophys Acta; 1998 Mar; 1380(1):64-74. PubMed ID: 9545536 [TBL] [Abstract][Full Text] [Related]
39. Established and experimental treatments for sickle cell disease. De Franceschi L; Corrocher R Haematologica; 2004 Mar; 89(3):348-56. PubMed ID: 15020275 [TBL] [Abstract][Full Text] [Related]